These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 19277036)

  • 1. Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib.
    Lemos C; Kathmann I; Giovannetti E; Calhau C; Jansen G; Peters GJ
    Br J Cancer; 2009 Apr; 100(7):1120-7. PubMed ID: 19277036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells.
    Huang WC; Chen YJ; Li LY; Wei YL; Hsu SC; Tsai SL; Chiu PC; Huang WP; Wang YN; Chen CH; Chang WC; Chang WC; Chen AJ; Tsai CH; Hung MC
    J Biol Chem; 2011 Jun; 286(23):20558-68. PubMed ID: 21487020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular folate status modulates the expression of BCRP and MRP multidrug transporters in cancer cell lines from different origins.
    Lemos C; Kathmann I; Giovannetti E; Beliën JA; Scheffer GL; Calhau C; Jansen G; Peters GJ
    Mol Cancer Ther; 2009 Mar; 8(3):655-64. PubMed ID: 19240161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folate deprivation induces BCRP (ABCG2) expression and mitoxantrone resistance in Caco-2 cells.
    Lemos C; Kathmann I; Giovannetti E; Dekker H; Scheffer GL; Calhau C; Jansen G; Peters GJ
    Int J Cancer; 2008 Oct; 123(7):1712-20. PubMed ID: 18623116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression. A role for BCRP in cellular folate homeostasis.
    Ifergan I; Shafran A; Jansen G; Hooijberg JH; Scheffer GL; Assaraf YG
    J Biol Chem; 2004 Jun; 279(24):25527-34. PubMed ID: 15047700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The EGFR pathway regulates BCRP expression in NSCLC cells: role of erlotinib.
    Porcelli L; Giovannetti E; Assaraf YG; Jansen G; Scheffer GL; Kathman I; Azzariti A; Paradiso A; Peters GJ
    Curr Drug Targets; 2014; 15(14):1322-30. PubMed ID: 25479544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib.
    Noguchi K; Kawahara H; Kaji A; Katayama K; Mitsuhashi J; Sugimoto Y
    Cancer Sci; 2009 Sep; 100(9):1701-7. PubMed ID: 19493273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.
    Li J; Cusatis G; Brahmer J; Sparreboom A; Robey RW; Bates SE; Hidalgo M; Baker SD
    Cancer Biol Ther; 2007 Mar; 6(3):432-8. PubMed ID: 17312388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gefitinib reverses breast cancer resistance protein-mediated drug resistance.
    Yanase K; Tsukahara S; Asada S; Ishikawa E; Imai Y; Sugimoto Y
    Mol Cancer Ther; 2004 Sep; 3(9):1119-25. PubMed ID: 15367706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
    Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
    Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells.
    Chen YJ; Huang WC; Wei YL; Hsu SC; Yuan P; Lin HY; Wistuba II; Lee JJ; Yen CJ; Su WC; Chang KY; Chang WC; Chou TC; Chou CK; Tsai CH; Hung MC
    PLoS One; 2011; 6(6):e21428. PubMed ID: 21731744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance.
    Shi Z; Parmar S; Peng XX; Shen T; Robey RW; Bates SE; Fu LW; Shao Y; Chen YM; Zang F; Chen ZS
    Oncol Rep; 2009 Feb; 21(2):483-9. PubMed ID: 19148526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
    Pick A; Wiese M
    ChemMedChem; 2012 Apr; 7(4):650-62. PubMed ID: 22354538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
    Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivity in estrogen receptor alpha negative fulvestrant-resistant MCF-7 cells.
    Liu H; Cheng D; Weichel AK; Osipo C; Wing LK; Chen B; Louis TE; Jordan VC
    Int J Oncol; 2006 Nov; 29(5):1237-46. PubMed ID: 17016657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological interplay between breast cancer resistance protein and gefitinib in epidermal growth factor receptor signaling.
    Katayama K; Shibata K; Mitsuhashi J; Noguchi K; Sugimoto Y
    Anticancer Res; 2009 Apr; 29(4):1059-65. PubMed ID: 19414346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance.
    Hegedüs C; Truta-Feles K; Antalffy G; Várady G; Német K; Ozvegy-Laczka C; Kéri G; Orfi L; Szakács G; Settleman J; Váradi A; Sarkadi B
    Biochem Pharmacol; 2012 Aug; 84(3):260-7. PubMed ID: 22548830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erlotinib antagonizes ABC transporters in acute myeloid leukemia.
    Lainey E; Sébert M; Thépot S; Scoazec M; Bouteloup C; Leroy C; De Botton S; Galluzzi L; Fenaux P; Kroemer G
    Cell Cycle; 2012 Nov; 11(21):4079-92. PubMed ID: 23095522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
    Nagashima S; Soda H; Oka M; Kitazaki T; Shiozawa K; Nakamura Y; Takemura M; Yabuuchi H; Fukuda M; Tsukamoto K; Kohno S
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):594-600. PubMed ID: 16520985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.
    Marchetti S; de Vries NA; Buckle T; Bolijn MJ; van Eijndhoven MA; Beijnen JH; Mazzanti R; van Tellingen O; Schellens JH
    Mol Cancer Ther; 2008 Aug; 7(8):2280-7. PubMed ID: 18723475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.